Belite Bio (ADR) (BLTE)
Develops oral investigational therapies for retinal and metabolic diseases.
Something off on this page? Send us feedback.
Develops investigational small-molecule therapies for degenerative retinal diseases and metabolic disease. It has no approved products or product-sales revenue; its lead oral candidate, tinlarebant, targets Stargardt disease and geographic atrophy, while LBS-009 targets metabolic disease.
Develops small-molecule therapies for degenerative retinal diseases and metabolic disease. Tinlarebant (LBS-008), a once-daily oral RBP4 antagonist, is its lead candidate for Stargardt disease and geographic atrophy; LBS-009 is a metabolic-disease program.
Clinical-development infrastructure spans the United States, Australia, Hong Kong, Shanghai, Switzerland and Japan. An in-house discovery and R&D team works with CROs, CMOs, investigators and clinical-trial sites.
Tinlarebant's STGD1 NDA submission is complete, but the therapy remains investigational, while DRAGON II and PHOENIX continue. With no approved products or product-sales revenue, development and commercialization depend on regulatory review, external clinical partners and further financing.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 14, 2026 | Morgan Stanley | Reiterate | Overweight | $191 | $206 |
| Aug 14, 2026 | Cantor Fitzgerald | Reiterate | Overweight | $270 | |
| Aug 14, 2026 | Mizuho Securities | Target | $215 | $220 | |
| Aug 12, 2026 | H.C. Wainwright | Reiterate | Buy | $200 | $214 |
| May 26, 2026 | Mizuho Securities | Target | $223 | $215 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $0 · Total debt $0 · Total assets $791.6M · Shareholders' equity $776.6M
- Revenue
- $0
- Operating income
- −$34.9M
- Net income
- −$28.4M
No dividends on record.
| Institutions75 holders · as of Mar 31, 2026 | 22.74% | 9.12M ADS | |
| Insiders5 holders · as of Aug 14, 2026 | 1.83% | 735.2K ADS | |
| Strategic holders1 holder · as of Jan 21, 2025 | 42.65% | 17.10M ADS | |
| Otherremainder | 32.78% | 13.14M ADS |
40.09M ADS as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Lin Bioscience International Ltd.Strategic | 42.65% | 17.10M | 13Gfiled Jan 21, 2025 ↗ |
Darwin Global Management, Ltd.Institution | 7.63% | 3.06M ADS | 13Fas of Mar 31, 2026 |
Paradigm Biocapital Advisors LPInstitution | 2.78% | 1.11M ADS | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 1.92% | 768,359 ADS | 13Fas of Mar 31, 2026 |
RTW Investments, LPInstitution | 1.78% | 715,332 ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 12, 2026 | Yu-Hsin Lin | director, officer: Chief Executive Officer | −365 | $180.35 |
| Aug 12, 2026 | Hao-Yuan Chuang | director, officer: Chief Financial Officer | −367 | $180.35 |
| Jun 18, 2026 | Hendrik Peter Scholl | officer: Chief Medical Officer | −10,000 | $145.24 |
| Jun 16, 2026 | Hendrik Peter Scholl | officer: Chief Medical Officer | −10,000 | $140.57 |
| May 7, 2026 | Nathan L. Mata | officer: Chief Scientific Officer | −666 | $153.21 |
- Biogen
Controls SYFOVRE, a commercial intravitreal therapy for GA
- Ocugen
Advances OCU410ST gene therapy in a pivotal STGD1 trial
- Annexon
Advances Phase 3 vonaprument for GA vision preservation
- Lineage Cell Therapeutics
Develops RG6501 (OpRegen), a cell therapy for GA
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Belite Bio (ADR) | $162.00 | +0.34% | $6.44B | — | — | — | — |
| Biogen | $222.65 | −0.03% | $32.90B | 39.4 | 16.8 | 3.3 | +3.4% |
| Ocugen | $1.32 | −0.38% | $447.6M | — | — | 97.7 | +8.4% |
| Annexon | $4.86 | −1.53% | $807.7M | — | — | — | — |
| Lineage Cell Therapeutics | $1.12 | +3.24% | $276.7M | — | — | 21.2 | −61.3% |
| Median | 39.4 | 16.8 | 21.2 | +3.4% |